Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Cellblastin
2. Lemblastine
3. Sulfate, Vinblastine
4. Velban
5. Velbe
6. Vinblastin Hexal
7. Vinblastina Lilly
8. Vinblastine
9. Vinblastinsulfat-gry
10. Vincaleukoblastine
1. 143-67-9
2. Velban
3. Velsar
4. Vinblastine (sulfate)
5. Velbe
6. Exal
7. Vlb Monosulfate
8. Alkaban-aq
9. 29060-le
10. Vinblastine Sulphate
11. Vincaleukoblastine,sulfate(1:1)
12. Nsc-49842
13. Mls000863275
14. Vincaleukoblastine, Sulfate (1:1) (salt)
15. N00w22yo2b
16. Belvan, Vlb
17. 29060le
18. Smr000058844
19. Vincaleucoblastine Sulfate
20. Dsstox_cid_27831
21. Dsstox_rid_82594
22. Dsstox_gsid_47853
23. Uniblastin
24. Rozevin Sulfate
25. 29060 Le
26. Cas-18556-44-0
27. Vincaleukoblastine, Sulfate
28. Unii-n00w22yo2b
29. Ccris 2584
30. Vinblastinesulfate
31. Vinblastini Sulfas
32. Chembl378544
33. Ncgc00095285-01
34. Einecs 205-606-0
35. Vinblastine Sulfate [usan:usp:jan]
36. Opera_id_960
37. Ai3-52943
38. Ncgc00181127-01
39. Schembl3549
40. Mls000069550
41. Mls002153253
42. Mls002207069
43. Vinblastine Sulfate [mi]
44. Vinblastine Sulfate [jan]
45. Dtxsid601017133
46. Hms2235e07
47. Hms3403n09
48. Vinblastine Sulfate [iarc]
49. Vinblastine Sulfate [usan]
50. Vinblastine Sulfate [vandf]
51. Vinblastine Sulfate [mart.]
52. Tox21_111498
53. Tox21_112735
54. Ac-821
55. Vinblastine Sulfate [usp-rs]
56. Vinblastine Sulfate [who-dd]
57. Vinblastine Sulfate [who-ip]
58. Akos015960580
59. Tox21_111498_1
60. Tox21_112735_1
61. Cs-1365
62. Ncgc00263548-01
63. Ncgc00344583-01
64. Vinblastine Sulfate [orange Book]
65. Hy-13780
66. Vinblastine Sulfate [ep Monograph]
67. Vinblastini Sulfas [who-ip Latin]
68. Vinblastine Sulfate [usp Monograph]
69. N2255
70. 143v679
71. Sr-01000000155
72. Vinblastine Sulfate Salt, Powder, >=96% (hplc)
73. Sr-01000000155-7
74. Q27077057
75. Vinblastine Sulfate, European Pharmacopoeia (ep) Reference Standard
76. Vinblastine Sulfate, United States Pharmacopeia (usp) Reference Standard
77. Methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(13s,15r,17s)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0?,??.0?,??]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0?,?.0?,?.0??,??]nonadeca-2(7),3,5,13-tetraene-10-carboxylate; Sulfuric Acid
78. Methyl (3ar,3a1r,4r,5s,5ar,10br)-4-acetoxy-3a-ethyl-9-((5s,7r,9s)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1h-indolizino[8,1-cd]carbazole-5-carboxylate Sulfate
1. Vincaleukoblastine Sulfate
2. Vinblastine Sulphate
3. Cellblastin
| Molecular Weight | 909.1 g/mol |
|---|---|
| Molecular Formula | C46H60N4O13S |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 10 |
| Exact Mass | 908.38775915 g/mol |
| Monoisotopic Mass | 908.38775915 g/mol |
| Topological Polar Surface Area | 237 Ų |
| Heavy Atom Count | 64 |
| Formal Charge | 0 |
| Complexity | 1780 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Vinblastine sulfate |
| PubMed Health | Vinblastine |
| Drug Label | Vinblastine sulfate is the salt of an alkaloid extracted from Vinca rosea Linn., a common flowering herb known as the periwinkle (more properly known as Catharanthus roseus G. Don). Previously, the generic name was vincaleukoblastine, abbreviated VLB... |
| Active Ingredient | Vinblastine sulfate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/vial; 1mg/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Eurohlth Intl |
| 2 of 2 | |
|---|---|
| Drug Name | Vinblastine sulfate |
| PubMed Health | Vinblastine |
| Drug Label | Vinblastine sulfate is the salt of an alkaloid extracted from Vinca rosea Linn., a common flowering herb known as the periwinkle (more properly known as Catharanthus roseus G. Don). Previously, the generic name was vincaleukoblastine, abbreviated VLB... |
| Active Ingredient | Vinblastine sulfate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/vial; 1mg/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Eurohlth Intl |
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Certificate Number : CEP 2020-065 - Rev 02
Issue Date : 2025-12-02
Type : Chemical
Substance Number : 748
Status : Valid
Registration Number : 306MF10066
Registrant's Address : 15 Hawkins Avenue, Epping 1,7460, Cape Town, South Africa
Initial Date of Registration : 2024-05-15
Latest Date of Registration :
NDC Package Code : 48954-588
Start Marketing Date : 1982-05-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-27
Pay. Date : 2017-11-27
DMF Number : 5335
Submission : 1984-04-13
Status : Active
Type : II
Certificate Number : R1-CEP 2004-073 - Rev 02
Issue Date : 2015-08-04
Type : Chemical
Substance Number : 748
Status : Valid
NDC Package Code : 69910-0002
Start Marketing Date : 2015-06-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39264
Submission : 2024-03-18
Status : Active
Type : II
NDC Package Code : 62158-0012
Start Marketing Date : 2025-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39944
Submission : 2025-01-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16240
Submission : 2002-11-11
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3499
Submission : 1979-04-05
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-261 - Rev 00
Issue Date : 2011-11-04
Type : Chemical
Substance Number : 748
Status : Valid
Registration Number : 220MF10116
Registrant's Address : BUDAPEST, GYOMROI UT 19-21, HUNGARY
Initial Date of Registration : 2008-04-28
Latest Date of Registration :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : Complete
Rev. Date : 2018-03-27
Pay. Date : 2017-11-27
DMF Number : 5335
Submission : 1984-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6499
Submission : 1986-07-28
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3499
Submission : 1979-04-05
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39944
Submission : 2025-01-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39264
Submission : 2024-03-18
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4978
Submission : 1983-07-06
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4883
Submission : 1983-04-04
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16240
Submission : 2002-11-11
Status : Inactive
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11284
Submission : 1995-01-03
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Certificate Number : R1-CEP 2004-073 - Rev 02
Status : Valid
Issue Date : 2015-08-04
Type : Chemical
Substance Number : 748
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Vinblastine Sulfate, Process 2
Certificate Number : CEP 2020-065 - Rev 02
Status : Valid
Issue Date : 2025-12-02
Type : Chemical
Substance Number : 748
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2007-300 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2015-07-08
Type : Chemical
Substance Number : 748

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Vinblastine Sulfate, New Process
Certificate Number : R0-CEP 2013-352 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2015-12-21
Type : Chemical
Substance Number : 748

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2005-261 - Rev 00
Status : Valid
Issue Date : 2011-11-04
Type : Chemical
Substance Number : 748

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Registration Number : 306MF10066
Registrant's Address : 15 Hawkins Avenue, Epping 1,7460, Cape Town, South Africa
Initial Date of Registration : 2024-05-15
Latest Date of Registration : 2024-05-15
Registration Number : 220MF10116
Registrant's Address : BUDAPEST, GYOMROI UT 19-21, HUNGARY
Initial Date of Registration : 2008-04-28
Latest Date of Registration : 2008-04-28

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-08-26
Valid Till : 2028-08-08
Written Confirmation Number : WC-0138
Address of the Firm : Plot No. 285, 286 & 287, Bommasandra — Jigani Link Road Industrial Area, KIADB...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
NDC Package Code : 69910-0002
Start Marketing Date : 2015-06-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 48954-588
Start Marketing Date : 1982-05-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62158-0012
Start Marketing Date : 2025-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
About the Company : MINAKEM is a cGMP custom manufacturer specializing in small molecule APIs, HPAPIs, and steroids. Its highly skilled R&D teams, supported by strong analytical and regulatory service...
About the Company : Minakem Montreal is developing and manufacturing small molecules APIs and advanced intermediates, including corticosteroids. Following efficient processes and methodologies, our em...
About the Company : Aspen API is a cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. The company supplies a broad portfolio of over 50 high-qual...
About the Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), phytochemicals, herba...
About the Company : Hubei Hongzhong Pharmaceutical Co., Ltd. was founded in 2007 and is located in Li Shizhen Pharmaceutical Industrial Park, Qichun County, Hubei Province. The company's products have...

About the Company : Established in the year 2004, Sakar is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injec...

About the Company : VINKEM - One Stop Solution for complete range ofOncology In-house API's & Finished dosage injectables in liquid vials andlyophilized form.State of Art cGMP facility with DMF and ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nivolumab, an antibody targeting PD-1, shows promise in treating Classical Hodgkin lymphoma.
Lead Product(s): Nivolumab,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area: Oncology Brand Name: Opdivo
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nivolumab,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fda Grants Priority Review to Bristol Myers Squibb's Opdivo Plus Chemotherapy for Hodgkin Lymphoma
Details : Nivolumab, an antibody targeting PD-1, shows promise in treating Classical Hodgkin lymphoma.
Product Name : Opdivo
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proceeds from the offering will be used to fund the clinical development of Cisplatin, a cytotoxic drug targeting DNA, to advance cancer treatment.
Lead Product(s): Cisplatin,Vinblastine Sulfate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Cytotoxic Drug
Sponsor: Alliance Global Partners
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cisplatin,Vinblastine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Alliance Global Partners
Deal Size : $4.0 million
Deal Type : Public Offering
Intensity Therapeutics Announces $4M Stock Offering
Details : The proceeds from the offering will be used to fund the clinical development of Cisplatin, a cytotoxic drug targeting DNA, to advance cancer treatment.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
October 31, 2025

Details:
Vinblastine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Lead Product(s): Vinblastine Sulfate,Brentuximab Vedotin,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: University of Alabama at Birmingham | Helen DeVos Children's Hospital | Nationwide Children’s Hospital | Memorial Sloan Kettering Cancer Center | University of Utah | Ohio State University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2025

Lead Product(s) : Vinblastine Sulfate,Brentuximab Vedotin,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : University of Alabama at Birmingham | Helen DeVos Children's Hospital | Nationwide Children’s Hospital | Memorial Sloan Kettering Cancer Center | University of Utah | Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Details : Vinblastine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Durvalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.
Lead Product(s): Durvalumab,Methotrexate,Vinblastine Sulfate,Doxorubicin Hydrochloride,Cisplatin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Durvalumab,Methotrexate,Vinblastine Sulfate,Doxorubicin Hydrochloride,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Durvalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 18, 2025

Details:
Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Lead Product(s): Methotrexate,Vinblastine Sulfate,Doxorubicin Hydrochloride,Cisplatin,Gemcitabine,Avelumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Merck Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024

Lead Product(s) : Methotrexate, Vinblastine Sulfate, Doxorubicin Hydrochloride, Cisplatin, Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
Lead Product(s): Cisplatin,2-Hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: SAKK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cisplatin,2-Hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : SAKK
Deal Size : Undisclosed
Deal Type : Collaboration
Intensity Therapeutics, Sakk Ink Agreement for Phase 2 Trial in Early-Stage Cancer
Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine,Pembrolizumab,Gemcitabine,Vinorelbine Tartrate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brentuximab Vedotin, Doxorubicin Hydrochloride, Vinblastine Sulfate, Dacarbazine, Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 18, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients ...
Details : Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 18, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Ad...
Details : ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 18, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Packaging :
Approval Date : 1985-11-18
Application Number : 89011
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : INJECTION
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : VELBAN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Packaging :
Approval Date : 1982-01-01
Application Number : 12665
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Packaging :
Approval Date : 1987-04-29
Application Number : 89515
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Packaging :
Approval Date : 1987-04-09
Application Number : 89395
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Packaging :
Approval Date : 1987-08-18
Application Number : 89565
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : Injectable; Injection
Dosage Strength : 1MG/ML
Packaging :
Approval Date :
Application Number : 89311
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : VINBLASTINE SULFATE
Dosage Form : Injectable; Injection
Dosage Strength : 10MG/VIAL
Packaging :
Approval Date :
Application Number : 89365
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Vinblastine
Dosage Form : Vinblastine 10Mg 10Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 10 mg 10 ml 1 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Approval Date : 1985-11-18
Application Number : 89011
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : VELBAN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1982-01-01
Application Number : 12665
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 1987-04-29
Application Number : 89515
RX/OTC/DISCN : RX
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Approval Date : 1987-04-09
Application Number : 89395
RX/OTC/DISCN : RX
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Approval Date : 1987-08-18
Application Number : 89565
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : Injectable; Injection
Dosage Strength : 1MG/ML
Approval Date :
Application Number : 89311
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : VINBLASTINE SULFATE
Dosage Form : Injectable; Injection
Dosage Strength : 10MG/VIAL
Approval Date :
Application Number : 89365
RX/OTC/DISCN :
RLD :
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Choose
Dosage Form : Powder For Solution For Injection
Dosage Strength : 10mg
Packaging :
Approval Date : 10-03-2023
Application Number : 28106648521
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Velbe
Dosage Form : Powder For Solution For Injection
Dosage Strength : 10mg
Packaging :
Approval Date : 23/05/1961
Application Number : 27821
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Vinblastina Stada
Dosage Form : Powder For Injectable Solution
Dosage Strength : 10MG
Packaging :
Approval Date : 01-01-1962
Application Number : 37275
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Choose
Dosage Form : Powder For Solution For Injection
Dosage Strength : 10mg
Packaging :
Approval Date : 28-03-1962
Application Number : 28100366461
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Velbe
Dosage Form : Powder For Solution For Injection
Dosage Strength : 10mg
Packaging :
Approval Date : 31-12-1963
Application Number : 1.96E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Vinblastine
Dosage Form : Vinblastine 10Mg 10Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 10 mg 10 ml 1 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Vinblastine Teva
Dosage Form : Solution For Injection
Dosage Strength : 1mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Regulatory Info :
Registration Country : Italy
Brand Name : Velbe
Dosage Form : Vinblastine 10Mg 1 Unit Parenteral Use
Dosage Strength : 1 ampoule EV 10 mg Groun
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Invalid
Registration Country : Malta
Brand Name : Vinblastine Sulphate
Dosage Form : Solution For Injection
Dosage Strength : 1MG/ML
Packaging :
Approval Date : 2007-07-02
Application Number :
Regulatory Info : Invalid
Registration Country : Malta

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Authorised
Registration Country : Malta
Brand Name : Vinblastine Sulphate Teva
Dosage Form : Solution For Injection
Dosage Strength : 1MG/ML
Packaging :
Approval Date : 2024-08-14
Application Number :
Regulatory Info : Authorised
Registration Country : Malta

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : VINBLASTINE SULFATE INJECTION
Dosage Form : SOLUTION
Dosage Strength : 1MG/ML
Packaging : 10ML
Approval Date :
Application Number : 2183056
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : VINBLASTINE SULPHATE INJECTION
Dosage Form : SOLUTION
Dosage Strength : 1MG/ML
Packaging : 13.5ML VIAL
Approval Date :
Application Number : 2401460
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : INJECTION
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info : Generic
Dosage : INJECTION
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Lyophilised Injection
Dosage Strength : 10MG/Vial
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Lyophilised Injection
Dosage Strength : 10MG/Vial
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG
Packaging : 10 ml + 0.9% w/v Sodium Chloride
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 10 ml + 0.9% w/v Sodium Chloride
Regulatory Info :
Dosage : Injection
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 10MG/10ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Lyophilized Injection
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Lyophilized Injection
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Tablet
Grade : Parenteral, Oral, Topical
Category : Parenteral, Solubilizers, Topical
Application : Parenteral
Excipient Details : Used as an osmolarity agent in culture media, tonicity adjuster in ophthalmics and parenterals solutions.
Pharmacopoeia Ref : On Request
Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised pa...
Ingredient(s) : Sodium Chloride Excipient
Dosage Form : Cream / Lotion / Ointment, Injectable / Parenteral
Grade : Parenteral and Topical
Category : Parenteral, Topical
Application : Parenteral, Topical
Excipients Web Link
Brand Name : Sodium Chloride USP
Application : Parenteral
Excipient Details : A & C's Sodium Chloride is an excipient meeting the USP monograph.
Excipients Web Link
Brand Name : NaCl Multi-compendial Low Endotoxin
Application : Parenteral
Excipient Details : A & C's Sodium Chloride multi-compendial low endotoxin is an excipient meeting USP-NF, EP, BP and JP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Low Endotoxin
Ingredient(s) : Sodium Chloride Excipient
Excipients Web Link
https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-hit-record-high-in-q1-2024-impacts-cancer-adhd-drugs-lilly-novo-ramp-up-production
Global Sales Information
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 2,754
Year : 2023
Prescribers : 11
Prescriptions : 27

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 4,018
Year : 2022
Prescribers : 16
Prescriptions : 42

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 4,648
Year : 2021
Prescribers : 15
Prescriptions : 39

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 3,980
Year : 2020
Prescribers : 11
Prescriptions : 39

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 4,520
Year : 2019
Prescribers : 16
Prescriptions : 55

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Vinblastine Sulfate
Drug Cost (USD) : 4,361
Year : 2018
Prescribers : 13
Prescriptions : 46

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Vinblastine 10Mg 10Ml 1 Units Pa...
Dosage Strength : 1 vial EV 10 mg 10 ml 1 mg/ml
Price Per Pack (Euro) : 10.07
Published in :
Country : Italy
RX/OTC/DISCN : Class H

CRINOS SpA
Dosage Form : Vinblastine 10Mg 1 Unit Parenter...
Dosage Strength : 1 ampoule EV 10 mg Groun
Price Per Pack (Euro) : 17.9
Published in :
Country : Italy
RX/OTC/DISCN : Class H

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
09 Jun 2025
Reply
31 May 2022
Reply
08 Feb 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Reply
11 May 2020
Reply
09 Aug 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
CAS Number : 143-67-9
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : V0300000
Batch No : 4
Price (€) : 79
Storage : -80°C ± 10°C

Vinblastine sulfate - reference spectrum
CAS Number : n/a
Quantity Per Vial : n/a
Sale Unit : 1
Order Code : V0305000
Batch No : 1
Price (€) : 79
Storage :

CAS Number : 2068-78-2
Quantity Per Vial : 4.96 mg
Sale Unit : 1
Order Code : V0400000
Batch No : 5
Price (€) : 79
Storage : -80°C ± 10°C

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
44
PharmaCompass offers a list of Vinblastine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vinblastine Sulfate manufacturer or Vinblastine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vinblastine Sulfate manufacturer or Vinblastine Sulfate supplier.
PharmaCompass also assists you with knowing the Vinblastine Sulfate API Price utilized in the formulation of products. Vinblastine Sulfate API Price is not always fixed or binding as the Vinblastine Sulfate Price is obtained through a variety of data sources. The Vinblastine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vinblastine Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vinblastine Sulfate, including repackagers and relabelers. The FDA regulates Vinblastine Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vinblastine Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vinblastine Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Vinblastine Sulfate supplier is an individual or a company that provides Vinblastine Sulfate active pharmaceutical ingredient (API) or Vinblastine Sulfate finished formulations upon request. The Vinblastine Sulfate suppliers may include Vinblastine Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Vinblastine Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Vinblastine Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Vinblastine Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Vinblastine Sulfate DMFs exist exist since differing nations have different regulations, such as Vinblastine Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vinblastine Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Vinblastine Sulfate USDMF includes data on Vinblastine Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vinblastine Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vinblastine Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Vinblastine Sulfate Drug Master File in Japan (Vinblastine Sulfate JDMF) empowers Vinblastine Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Vinblastine Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Vinblastine Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Vinblastine Sulfate suppliers with JDMF on PharmaCompass.
A Vinblastine Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Vinblastine Sulfate Certificate of Suitability (COS). The purpose of a Vinblastine Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Vinblastine Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Vinblastine Sulfate to their clients by showing that a Vinblastine Sulfate CEP has been issued for it. The manufacturer submits a Vinblastine Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Vinblastine Sulfate CEP holder for the record. Additionally, the data presented in the Vinblastine Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Vinblastine Sulfate DMF.
A Vinblastine Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Vinblastine Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Vinblastine Sulfate suppliers with CEP (COS) on PharmaCompass.
A Vinblastine Sulfate written confirmation (Vinblastine Sulfate WC) is an official document issued by a regulatory agency to a Vinblastine Sulfate manufacturer, verifying that the manufacturing facility of a Vinblastine Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vinblastine Sulfate APIs or Vinblastine Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Vinblastine Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Vinblastine Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vinblastine Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vinblastine Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vinblastine Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vinblastine Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vinblastine Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vinblastine Sulfate suppliers with NDC on PharmaCompass.
Vinblastine Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vinblastine Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vinblastine Sulfate GMP manufacturer or Vinblastine Sulfate GMP API supplier for your needs.
A Vinblastine Sulfate CoA (Certificate of Analysis) is a formal document that attests to Vinblastine Sulfate's compliance with Vinblastine Sulfate specifications and serves as a tool for batch-level quality control.
Vinblastine Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Vinblastine Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vinblastine Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Vinblastine Sulfate EP), Vinblastine Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vinblastine Sulfate USP).